Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Jóźwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. Reijers ILM, et al. Among authors: van akkooi acj, van der hage ja, van de wiel ba, van houdt wj, van der veldt aam, van de poll franse lv, van den heuvel nmj. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. Nat Med. 2022. PMID: 35661157 Clinical Trial.
Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM. Tjin EP, et al. Among authors: van de wiel ba, van de kasteele w. Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10. Cancer Immunol Res. 2014. PMID: 24894091
Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized? : A Retrospective, Multicenter Cohort Study.
Oude Ophuis CM, van Akkooi AC, Hoekstra HJ, Bonenkamp JJ, van Wissen J, Niebling MG, de Wilt JH, van der Hiel B, van de Wiel B, Koljenović S, Grünhagen DJ, Verhoef C. Oude Ophuis CM, et al. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1172-80. doi: 10.1245/s10434-015-4602-4. Epub 2015 May 27. Ann Surg Oncol. 2015. PMID: 26014150 Free PMC article.
The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases.
van Wissen J, van der Hiel B, van der Hage JA, van de Wiel BA, Wouters MW, van Akkooi AC. van Wissen J, et al. Among authors: van der hage ja, van de wiel ba, van akkooi ac, van der hiel b. Ann Surg Oncol. 2016 Jul;23(7):2323-9. doi: 10.1245/s10434-016-5142-2. Epub 2016 Feb 26. Ann Surg Oncol. 2016. PMID: 26920386
Blue dye can be safely omitted in most sentinel node procedures for melanoma.
van der Ploeg IM, Madu MF, van der Hage JA, Wouters MW, Klop WM, van der Hiel B, van de Wiel BA, van Akkooi AJ. van der Ploeg IM, et al. Among authors: van der hage ja, van de wiel ba, van akkooi aj, van der hiel b. Melanoma Res. 2016 Oct;26(5):464-8. doi: 10.1097/CMR.0000000000000271. Melanoma Res. 2016. PMID: 27232099
Clinical Prognostic Markers in Stage IIIB Melanoma.
Madu MF, Wouters MW, Klop WM, van der Hiel B, van de Wiel BA, Jóźwiak K, van der Hage JA, van Akkooi AC. Madu MF, et al. Among authors: van de wiel ba, van der hage ja, van akkooi ac, van der hiel b. Ann Surg Oncol. 2016 Dec;23(13):4195-4202. doi: 10.1245/s10434-016-5396-8. Epub 2016 Jul 5. Ann Surg Oncol. 2016. PMID: 27380642
Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group. van der Hiel B, et al. Among authors: van de wiel ba, van den eertwegh ajm. BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5. BMC Cancer. 2017. PMID: 28915798 Free PMC article.
Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria.
Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, Jóźwiak K, Klop WMC, Wouters MWJM, van Akkooi ACJ, Van de Wiel BA. Madu MF, et al. Among authors: van akkooi acj, van de wiel ba. Eur J Cancer. 2017 Dec;87:212-215. doi: 10.1016/j.ejca.2017.09.002. Epub 2017 Oct 3. Eur J Cancer. 2017. PMID: 28986137 No abstract available.
59 results